Published in Blood on July 10, 2003
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med (2005) 7.01
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 6.60
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood (2008) 3.77
G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood (2005) 3.76
Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med (2005) 3.21
CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest (2010) 2.38
Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood (2009) 2.25
Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood (2008) 2.16
Robo4 cooperates with CXCR4 to specify hematopoietic stem cell localization to bone marrow niches. Cell Stem Cell (2011) 1.98
Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol (2011) 1.98
Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med (2011) 1.96
CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood (2009) 1.83
AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood (2006) 1.79
G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood (2006) 1.76
Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med (2011) 1.75
Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood (2011) 1.73
Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy (2009) 1.73
Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. Am J Physiol Cell Physiol (2012) 1.67
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood (2014) 1.66
The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood (2011) 1.65
Pharmacological mobilization of endogenous stem cells significantly promotes skin regeneration after full-thickness excision: the synergistic activity of AMD3100 and tacrolimus. J Invest Dermatol (2014) 1.61
Stem-cell ecology and stem cells in motion. Blood (2008) 1.61
CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci U S A (2010) 1.61
Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia (2011) 1.59
CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism. Circulation (2012) 1.53
The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ Res (2010) 1.46
Mobilization of endogenous stem cell populations enhances fracture healing in a murine femoral fracture model. Cytotherapy (2013) 1.44
Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia (2011) 1.44
CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res (2011) 1.42
The neuroblast and angioblast chemotaxic factor SDF-1 (CXCL12) expression is briefly up regulated by reactive astrocytes in brain following neonatal hypoxic-ischemic injury. BMC Neurosci (2005) 1.38
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant (2015) 1.38
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood (2011) 1.37
Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand. Curr Opin Hematol (2008) 1.33
Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med (2008) 1.33
Mobilization as a preparative regimen for hematopoietic stem cell transplantation. Blood (2006) 1.28
Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol (2009) 1.26
Chemical approaches to stem cell biology and therapeutics. Cell Stem Cell (2013) 1.25
The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood (2007) 1.25
Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med (2009) 1.24
Neutrophil mobilization from the bone marrow during polymicrobial sepsis is dependent on CXCL12 signaling. J Immunol (2011) 1.21
CD34-positive stem cells: in the treatment of heart and vascular disease in human beings. Tex Heart Inst J (2011) 1.21
Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood (2005) 1.20
Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model. PLoS One (2010) 1.12
Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer (2014) 1.11
Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J Med Chem (2012) 1.10
Mapping the ligand-binding site on a G protein-coupled receptor (GPCR) using genetically encoded photocrosslinkers. Biochemistry (2011) 1.09
Advances in stem cell mobilization. Blood Rev (2014) 1.09
Strategies to target long-lived plasma cells for treating hemophilia A inhibitors. Cell Immunol (2016) 1.07
Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia (2011) 1.06
The increase in surface CXCR4 expression on lung extravascular neutrophils and its effects on neutrophils during endotoxin-induced lung injury. Cell Mol Immunol (2011) 1.05
The intricate role of CXCR4 in cancer. Adv Cancer Res (2014) 1.04
Plerixafor. Nat Rev Drug Discov (2009) 1.04
Chemokine-mobilized adult stem cells; defining a better hematopoietic graft. Leukemia (2007) 1.04
Challenges for heart disease stem cell therapy. Vasc Health Risk Manag (2012) 1.02
Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant (2007) 1.00
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother (2007) 1.00
Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res (2007) 1.00
Home sweet home: the tumor microenvironment as a haven for regulatory T cells. Front Immunol (2013) 0.99
Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke. J Cereb Blood Flow Metab (2013) 0.99
The long road to the thymus: the generation, mobilization, and circulation of T-cell progenitors in mouse and man. Semin Immunopathol (2008) 0.98
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol (2010) 0.96
Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer J (2012) 0.96
Antagonism of stromal cell-derived factor-1alpha reduces infarct size and improves ventricular function after myocardial infarction. Pflugers Arch (2007) 0.96
Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes (2010) 0.95
Stromal derived factor 1α: a chemokine that delivers a two-pronged defence of the myocardium. Pharmacol Ther (2014) 0.95
CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis (2012) 0.94
Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing. Biomed Res Int (2013) 0.94
Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major. Hum Gene Ther (2013) 0.93
FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc. Blood (2006) 0.93
A novel CXCR4 antagonist derived from human SDF-1beta enhances angiogenesis in ischaemic mice. Cardiovasc Res (2009) 0.93
Plasminogen regulates stromal cell-derived factor-1/CXCR4-mediated hematopoietic stem cell mobilization by activation of matrix metalloproteinase-9. Arterioscler Thromb Vasc Biol (2011) 0.92
Discovery of very late antigen-4 (VLA-4, alpha4beta1 integrin) allosteric antagonists. J Biol Chem (2010) 0.91
Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant (2010) 0.91
Mobilization of hematopoietic stem cells from the bone marrow niche to the blood compartment. Stem Cell Res Ther (2011) 0.91
Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood (2011) 0.90
The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia (2013) 0.89
Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis. Exp Hematol (2010) 0.89
AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica (2011) 0.88
Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms. Methods Mol Biol (2012) 0.88
Progenitor cell mobilization and recruitment: SDF-1, CXCR4, α4-integrin, and c-kit. Prog Mol Biol Transl Sci (2012) 0.87
Bone marrow endothelial progenitors augment atherosclerotic plaque regression in a mouse model of plasma lipid lowering. Stem Cells (2012) 0.87
Space-time considerations for hematopoietic stem cell transplantation. Eur J Immunol (2008) 0.87
Expression of the chemokine receptor CXCR7 in CXCR4-expressing human 143B osteosarcoma cells enhances lung metastasis of intratibial xenografts in SCID mice. PLoS One (2013) 0.86
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood (2012) 0.86
Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol (2013) 0.86
Niche competition and cancer metastasis to bone. J Clin Invest (2011) 0.85
CXCR4 and a cell-extrinsic mechanism control immature B lymphocyte egress from bone marrow. J Exp Med (2014) 0.85
Physiology and pharmacology of plerixafor. Transfus Med Hemother (2013) 0.85
CXCR4 Expression and Treatment with SDF-1α or Plerixafor Modulate Proliferation and Chemosensitivity of Colon Cancer Cells. Transl Oncol (2013) 0.85
Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche. Cancer Res (2015) 0.85
Initial assessment of the role of CXC chemokine receptor 4 after polytrauma. Mol Med (2012) 0.84
A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol (2011) 0.83
Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction. Curr Top Med Chem (2012) 0.82
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med (2005) 7.01
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
Achieving a high-performance health care system with universal access: what the United States can learn from other countries. Ann Intern Med (2007) 5.25
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06
NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem (2003) 3.98
Modulation of hematopoietic stem cell homing and engraftment by CD26. Science (2004) 3.92
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood (2009) 3.84
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood (2007) 3.73
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol (2004) 3.50
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood (2008) 3.11
The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood (2006) 2.82
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood (2005) 2.79
Umbilical cord blood transplantation: the first 25 years and beyond. Blood (2013) 2.79
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol (2003) 2.71
SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell (2008) 2.67
Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol (2007) 2.60
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Moderate-intensity exercise reduces the incidence of colds among postmenopausal women. Am J Med (2006) 2.53
A noncytotoxic DsRed variant for whole-cell labeling. Nat Methods (2008) 2.34
Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia. Exp Hematol (2003) 2.25
Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr (2006) 2.25
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr (2004) 2.21
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17
Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation. Cell Stem Cell (2013) 2.12
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol (2004) 2.08
Does displaying the class results affect student discussion during peer instruction? CBE Life Sci Educ (2010) 2.04
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92
Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion (2002) 1.89
Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. J Leukoc Biol (2003) 1.80
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest (2016) 1.75
Immune responses in 4-1BB (CD137)-deficient mice. J Immunol (2002) 1.74
Preparing for a consumer-driven genomic age. N Engl J Med (2010) 1.72
Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion (2005) 1.71
CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 1.70
SDF-1/CXCL12 enhances survival and chemotaxis of murine embryonic stem cells and production of primitive and definitive hematopoietic progenitor cells. Stem Cells (2005) 1.68
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65
Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol (2002) 1.63
Frequent intentional weight loss is associated with lower natural killer cell cytotoxicity in postmenopausal women: possible long-term immune effects. J Am Diet Assoc (2004) 1.61
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. Leuk Lymphoma (2009) 1.61
High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci U S A (2003) 1.60
Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol (2009) 1.59
Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma (2003) 1.59
Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells. J Immunol (2006) 1.56
AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol (2002) 1.54
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol (2013) 1.53
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant (2013) 1.51
Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J Biol Chem (2003) 1.50
Identification of a massive reserve of hematopoietic progenitors in mice. Stem Cells Dev (2005) 1.50
Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev (2007) 1.50
Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med (2012) 1.49
Checkpoint-apoptosis uncoupling in human and mouse embryonic stem cells: a source of karyotpic instability. Blood (2007) 1.48
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood (2012) 1.47
New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant (2009) 1.46
Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer (2008) 1.46
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet (2013) 1.45
Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med (2010) 1.42
Analysis of T-cell receptor gene rearrangement for predicting clinical outcome in patients with cutaneous T-cell lymphoma: a comparison of Southern blot and polymerase chain reaction methods. Arch Dermatol (2005) 1.41
Apparent CD19 expression by natural killer cells: a potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia. Cytometry B Clin Cytom (2014) 1.41
Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood (2003) 1.40
P21waf-1-Chk1 pathway monitors G1 phase microtubule integrity and is crucial for restriction point transition. Cell Cycle (2002) 1.40
Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. Biochemistry (2003) 1.40
G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev (2012) 1.40
Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol (2002) 1.39
Severe congenital neutropenia. Semin Hematol (2006) 1.38
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood (2011) 1.37
Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol (2007) 1.37
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol (2010) 1.36
SIRT1 deficiency compromises mouse embryonic stem cell hematopoietic differentiation, and embryonic and adult hematopoiesis in the mouse. Blood (2010) 1.36